1stOncology™: Cancer Intelligence Service – Page 5900 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call

On February 21, 2023 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023 (Press release, Natera, FEB 21, 2023, View Source [SID1234627491]). Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Earnings Conference Call Information:

Event:

Natera’s Fourth Quarter and Year-End 2022 Financial Results

Date:

Tuesday, Feb. 28, 2023

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

1 (888) 770-7321, Domestic

1 (929) 201-7107, International

Conference ID:

7684785

Webcast:

View Source

A webcast replay will be available at investor.natera.com.

Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast

On February 21, 2023 Nordic Nanovector ASA (OSE: NANOV) reported that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023 (Press release, Nordic Nanovector, FEB 21, 2023, View Source [SID1234627490]).

A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes, will be held in-person and webcast live beginning at 8:30am CET.

VENUE: ADVOKATFIRMAET CLP DA, Sommerrogata 13, 0255 Oslo

Questions can be submitted in advance to [email protected]

The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022 from 7:00am CET the same day.

IR enquiries

Ludvik Sandnes, Interim CEO & CFO
+47 907 43 017
[email protected]

Vysioneer Announces Data Sharing Agreement with Pfizer to Augment Oncology Clinical Trials with Artificial Intelligence

On February 21, 2023 Vysioneer, a pioneer in AI for Oncology, reported a data sharing agreement with Pfizer, a global leader in pharmaceuticals (Press release, Vysioneer, FEB 21, 2023, View Source [SID1234627489]). The agreement aims to lay the foundation for the application of AI in oncology clinical trials. Vysioneer’s AI technology provides objective tumor response assessments and unlocks novel biomarkers that cannot be derived by human readers due to time and resources constraints, to predict patient outcomes at earliest timepoints.

As part of the agreement, Vysioneer gains access to one of Pfizer’s oncology clinical trial datasets to apply Vysioneer’s advanced machine learning techniques to facilitate the drug efficacy assessment process, thereby allowing Pfizer to assess drug efficacy with greater granularity and explore advanced biomarkers and novel endpoints.

The current standard to measure how well a cancer patient responds to treatment, such as response evaluation criteria in solid tumors (RECIST) is labor-intensive and prone to intra- and inter-reader variability by human readers. The use of AI has the potential to markedly improve clinical trial image reading processes as well as enhance the ability to provide more granular insights down to every single tumor. Through successful use of this valuable technology, Vysioneer and Pfizer hope it will lead to expanded clinical trial use cases, and ultimately, better patient care.

"We are thrilled to collaborate with Pfizer on this data sharing agreement. Pfizer has continually led the biopharma industry into the next wave of innovation, and we look forward to offering our AI technology to support their efforts," said Jen-Tang Lu, Chief Executive Officer of Vysioneer. "By objectively assessing drug efficacy on a large scale and uncovering new endpoints that more accurately reflect patient outcomes, we have a strong opportunity to significantly de-risk clinical trials and ensure that cancer patients receive the right treatment promptly."

Learn more at www.vysioneer.com.

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

On February 21, 2023 Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, reported that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento’s $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento’s chapter 11 case, which was filed on February 13, 2023 (Press release, Sorrento Therapeutics, FEB 21, 2023, View Source [SID1234627488]).

The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of the financing is currently set for March 29, 2023.

Dr. Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: "We are pleased to have received approval from the Court for this financing, which will ensure Sorrento has the liquidity and ability to continue normal business operations, including the payment of employee wages and benefits and post-petition vendor obligations. We will continue our important work of developing new and innovative therapies for patients struggling with cancer, intractable pain, infectious disease, and more."

As of its chapter 11 filing, Sorrento had over approximately $1 billion in assets. However, due to the possibility of certain actions by a litigation creditor, Sorrento and its wholly-owned, non-operating subsidiary Scintilla Pharmaceuticals, Inc. sought chapter 11 relief to safeguard its business and ensure the continuation of business operations, while protecting and maximizing value for stakeholders.

Scilex Holding Company (Nasdaq: SCLX, "Scilex"), which is majority-owned by Sorrento, is not a debtor in Sorrento’s chapter 11 case. Scilex is continuing to operate its business as usual, focusing on growing revenues, offering innovative, non-opioid pain management products, and developing meaningfully differentiated programs that address significant unmet needs and lead to better health outcomes for the millions of acute and chronic pain patients.

Latham & Watkins LLP and Jackson Walker LLP are serving as legal counsel to Sorrento. M3 Partners is serving as restructuring advisor.

TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company’s Development of Allogeneic Gamma-Delta T cell Therapies

On February 21, 2023 TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, reported the publication of a paper entitled, "A Phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia" in Clinical Lymphoma, Myeloma and Leukemia, a monthly peer reviewed journal (Press release, TC Biopharm, FEB 21, 2023, View Source [SID1234627487]).

The article highlights the abilities of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia.  The publication can be accessed online through the portal ScienceDirect at "A phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia. – ScienceDirect"

"I feel privileged to be part of the team that achieved the successful publication on our phase I trial using OmnImmune (haploidentical allogeneic γδ T lymphocytes) in advanced AML patients," said Dr. Emilio Cosimo, Director of Product Development. "The study shows the safety of this type of cell therapy and is the basis for TCB’s next steps in the allogeneic cell therapy sector."

Dr. Jan Vydra, Institute Of Hematology And Blood Transfusion, commented, "The results of our phase I clinical trial of γδ T cell immunotherapy of advanced AML support further research and development of this cell therapy platform, as it was shown to be both safe and feasible in this setting."

"This marks the first publication generated by TC Biopharm, a hallmark moment for our company and our team to be recognized within the industry," said Bryan Kobel, CEO of TC BioPharm. "I’d like to thank Dr. Vydra for all his hard work running the study and our former clinical director, Tomasz Zaremba, as well as Angela Scott, Dr. Mike Leek, Dr. Sebastian Wanless, Dr. Emilio Cosimo and the rest of the contributors. We look forward to additional publications in the future from our team."